Mainz, May 10 – 12 2016 – TRON at CIMT 2016 “Mechanisms of Efficacy in Cancer Immunotherapy” Looking forward to the 2016 Annual Meeting of Cancer Immunotherapy in Mainz. Connect with us at the booth A021 or at any of our posters.
Archive | links Spotlight
TRON at
TRON Review in Clinical Cancer Research
Mainz, April 2016 – Review in CCR Focus “Opportunities and Challenges in Cancer Immunotherapy”: “Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines” TRON and BioNTech scientists have written an overview of the clinical development of individualized neoepitope cancer vaccines, which is published now as CCR Focus Review article in Clinical Cancer Research.
TRON / BioNTech in Nature Medicine News
Mainz, February 2016TRON/BioNTech in Nature Medicine News Feature: “Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment”TRONs efforts to develop individualized cancer vaccines based on tumor-specific mutations is covered in a recent News Feature published in Nature Medicine.For more information please click the Link below, which will direct you to the Nature
Prof. Peer from the Tel Aviv University (TAU), Israel, visiting TRON
Mainz, October 2015 – TRON Seminar in Translational Oncology“RNA Therapeutics : New Era in Personalized Medicine?” Prof. Dan Peer, PhD – Department of Cell Research and Immunology, Tel Aviv University (TAU), Israel5 PM, Lecture Hall Building 708, University Medical Center MainzLangenbeckstr. 1, 55131 Mainz, Germany
Prof. Schoenberger from the La Jolla Institute for Allergy and Immunology visiting TRON
Mainz, July 2015 – TRON has the honor to host visiting Prof. Stephen Schoenberger at its facilities to promote international scientific interactions and facilitate collaborations in the fields of Immunology and Immunotherapy. Prof Schoenberger is co-author on a recent publication in Nature by TRON scientists focusing on mutated epitopes in cancer. During his time at TRON
Visit of a delegation from the Sultanate of Oman to TRON
Mainz, June 2015 – On June 1st and with generous support of the Ministry of Economics of Rhineland Palatinate, TRON welcomed a high-ranking delegation from the Sultanate of Oman for discussions on tasks and results of previous scientific works at TRON. Prof. Dr. Ulrich Förstermann of the Mainz University Medical Center also took part in the
TRON is part of the Cancer Research Consortium “Immuno-Transporter” to collaborate to develop innovative approaches in the field of cancer immunotherapy
Mainz, June, 2015 – The consortium partners will jointly develop methods to achieve tumor-specific activation of a patient’s immune system to make it recognize, target and fight cancer The newly established “IMMUNO-TRANSPORTER” consortium will collaborate to develop innovative approaches in the field of cancer immunotherapy.
TRON is part of the European Bioinformatics Research Consortium on personalised cancer immunotherapy
Mainz, May 1, 2015 – Experts in bioinformatics and cancer immunology to develop an Advanced bioinformatics platform for personalised cancer immunotherapy On May 1st, TRON under the leadership of Prof. Dr. med. Ugur Sahin started an innovative research project on personalised cancer immunotherapy.
Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
Mainz, April 23, 2015 – Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs Neue immunologische Erkenntnisse und technologische Fortschritte ebnen den Weg für maßgeschneiderte Krebsimpfstoffe / klinische Studie läuft bereits
Call for Papers: RNA Vaccination Therapy
Mainz, February 28, 2015 – TRON IDC Heads to lead Special Edition in Journal of Immunology Research In the field of therapeutic cancer vaccination in vitro transcribed synthetic mRNA (IVT RNA) has gained high interest in the recent years as a drug format not only for cancer immunotherapy, but also for the development of antiviral
Medizin des 21. Jahrhunderts
Mainz, November 26, 2014 – “In the lecture series “University in the City Hall,” scientists of the Mainz University Medical Center will present a range of current research topics to the general public. In addition to looking at how research is transformed into clinical application, they will also be outlining concepts for innovative future treatments.”
Genomics-guided RNA-based personalized cancer vaccines
Mainz, October 16, 2014 – Cancer is a disease caused by DNA mutations. 95% of the mutations in a tumor are unique to that single patient and only a small number of mutations are shared between patients. Therefore, a mutation-targeting individualized therapy would benefit each single patient. In the recent edition of the British Journal of
